Delta Air Lines posted a $607 million loss in the first quarter as the COVID-19 crisis forced the airline to cut up to 85% of its scheduled flights....
Macy’s, Inc. (M) is reportedly seeking to raise as much as $5 billion in debt as it is struggling with depressed retail sales after government restrictions to contain the coronavirus pandemic forced the closure of all of the department chain’s stores.According to the debt plan, the department chain will to use its inventory as collateral to raise $3 billion and real estate assets to raise $1 billion to $2 billion, CNBC reported.All of the department chain's 775 stores have been closed since March 18. Macy’s had also announced that it is suspending its quarterly dividend, drawing down on its credit line, freezing both hiring and spending, stopping capital spending, reducing receipts, and cancelling some orders and extending payment terms.This month, Macy’s said that its CFO and Executive Vice President Paula Price will leave the company adding more uncertainty as to how the department chain will navigate its cost-cutting plan and saving measures...
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Arvinas Inc (NASDAQ: ARVN) * Exelixis, Inc. (NASDAQ: EXEL) * GenMark Diagnostics, Inc (NASDAQ: GNMK) * Keros Therapeutics Inc (NASDAQ: KROS) * Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) * Moderna Inc (NASDAQ: MRNA) * OraSure Technologies, Inc. (NASDAQ: OSUR) * Repro-Med Systems, Inc. (NASDAQ: KRMD) * Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 21) * Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)(announced pricing of $20 million common stock offering) * Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) * Viveve Medical Inc (NASDAQ: VIVE)Stocks In Focus Novartis' Cell Therapy Gets Regenerative Medicine Advanced Therapy Designation For Follicular Lymphoma Novartis AG (NYSE: NVS) said the FDA granted Regenerative Medicine Advanced Therapy designation...
Stock futures rose Wednesday morning, recovering some losses after a sell-off in risk assets a day earlier sent the S&P 500 to its largest one-day drop since April 1....
Gilead Sciences (GILD) and its Kite unit have entered into a three-year cancer immunotherapy research collaboration with oNKo-innate. The goal: to discover and develop next-generation drug and engineered cell therapies focused on natural killer (NK) cells.Current cancer immunotherapy approaches primarily focus on T cell mediated anti-tumor immunity. Like T cells, NK cells are a class of lymphocytes (white blood cells) that play a critical role in the immune system. Both NK cells and T cells each have the potential to attack cancer cells, but each have different mechanisms for tumor cell killing.According to Gilead, appropriately activated and targeted NK cells may represent a differentiated approach that would be potentially complementary and synergistic with T cell mediated strategies.Financial terms of the deal were not disclosed, but oNKo-innate will receive an upfront payment and potential additional payments based on achievement of certain milestones.Specifically, oNKo-innate will use genome-wide screening techniques and its proprietary technology...
(Bloomberg) -- Facebook Inc. will invest $5.7 billion in the digital assets controlled by Asia’s richest man, the U.S. social-networking giant’s biggest deal since the 2014 purchase of WhatsApp as it seeks a broader foothold in its biggest global market.The U.S. company will buy about 10% of Jio Platforms, becoming the largest minority shareholder, Reliance Industries Ltd. said in a statement Wednesday. Separately, Facebook said the deal would bring together JioMart, an e-commerce venture of Mukesh Ambani and its WhatsApp platform to enable people to connect with businesses.Shares of Reliance Industries jumped 10% on Wednesday in Mumbai, helping the Indian tycoon reclaim the title of Asia’s wealthiest person from Alibaba Group Holding Ltd. founder Jack Ma. The rally compares with the 2.4% gain in India’s benchmark S&P BSE Sensex index.Jio Platforms, a wholly owned unit of Reliance Industries, brings together Jio’s digital apps, ecosystems and the wireless platform offered by telecommunications...
